The U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee has a lot to discuss Nov. 17, but only one voting question: Does the evidence demonstrate that Merck & Co. Inc.’s gefapixant provides a clinically meaningful benefit to adults with refractory or unexplained chronic cough?
Acquiring Bellus Health gives GSK a drug for recurrent chronic cough that could offer a better side effect profile compared to a Merck drug that addresses the same target. Bayer was also pursuing the target, but stopped work on its drug candidate last year.
BELLUS Health Inc. announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release formulation of camlipixant in comparison to a twice-daily. | April 6, 2023